Cost-effectiveness of noninvasive central blood pressure monitoring in the diagnosis of hypertension

American Journal of Hypertension

Volumn 28, Issue 5, 2015, Pages 604-614

  Cheng, Hao Min ^a,b,c   Pearson, Alan ^c   Sung, Shih Hsien ^a,b   Yu, Wen Chung ^a,b   Chen, Chen Huan ^a,b,c   Karnon, Jonathan ^d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Blood pressure; Central blood pressure; Cost effectiveness analysis; Hypertension

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD PRESSURE CUFF; BLOOD PRESSURE MONITORING; CENTRAL BLOOD PRESSURE MONITORING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; OUTCOME ASSESSMENT; POPULATION; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; COST BENEFIT ANALYSIS; ECONOMICS; MIDDLE AGED; PATHOPHYSIOLOGY; STATISTICAL MODEL;

ADULT; AGED; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MODELS, ECONOMIC;

EID: 84940753261     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpu214     Document Type: Article

References (75)

1. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ; Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360:1347-1360.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005; 365:217-223.
3. McManus RJ, Caulfield M, Williams B; National Institute for Health and Clinical Excellence. NICE hypertension guideline 2011: evidence based evolution. BMJ 2012; 344:e181.
4. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
6. Giles TD, Berk BC, Black HR, Cohn JN, Kostis JB, Izzo JL Jr, Weber MA. Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich) 2005; 7:505-512.
7. Task Force Members. 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34:2159-2219.
8. Mayor S. Hypertension diagnosis should be based on ambulatory blood pressure monitoring, NICE recommends. BMJ 2011; 343:d5421.
9. O'Brien E. End of the Joint National Committee heritage? Hypertension 2014; 63:904-906.
10. Nichols WW, O'Rourke MF, Vlachopoulos C. McDonald's Blood Flow in Arteries: Theoretic, Experimental and Clinical Principles, 6th edn. Arnold: London, 2011.
11. Segers P, Mahieu D, Kips J, Rietzschel E, De Buyzere M, De Bacquer D, Bekaert S, De Backer G, Gillebert T, Verdonck P, Van Bortel L; Asklepios investigators. Amplification of the pressure pulse in the upper limb in healthy, middle-aged men and women. Hypertension 2009; 54:414-420.
12. Kelly RP, Gibbs HH, O'Rourke MF, Daley JE, Mang K, Morgan JJ, Avolio AP. Nitroglycerin has more favourable effects on left ventricular afterload than apparent from measurement of pressure in a peripheral artery. Eur Heart J 1990; 11:138-144.
13. Takazawa K, Tanaka N, Takeda K, Kurosu F, Ibukiyama C. Underestimation of vasodilator effects of nitroglycerin by upper limb blood pressure. Hypertension 1995; 26:520-523.
14. Jiang XJ, O'Rourke MF, Jin WQ, Liu LS, Li CW, Tai PC, Zhang XC, Liu SZ. Quantification of glyceryl trinitrate effect through analysis of the synthesised ascending aortic pressure waveform. Heart 2002; 88:143-148.
15. Mackenzie IS, McEniery CM, Dhakam Z, Brown MJ, Cockcroft JR, Wilkinson IB. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009; 54:409-413.
16. Protogerou AD, Stergiou GS, Vlachopoulos C, Blacher J, Achimastos A. The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part II: evidence for specific class-effects of antihypertensive drugs on pressure amplification. Curr Pharm Des 2009; 15:272-289.
17. London GM, Asmar RG, O'Rourke MF, Safar ME; REASON Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004; 43:92-99.
18. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213-1225.
19. de Luca N, Asmar RG, London GM, O'Rourke MF, Safar ME. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J Hypertens 2004; 22:1623-1630.
20. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, Umans JG, Howard BV. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 2007; 50:197-203.
21. Wang KL, Cheng HM, Chuang SY, Spurgeon HA, Ting CT, Lakatta EG, Yin FC, Chou P, Chen CH. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? J Hypertens 2009; 27:461-467.
22. Jankowski P, Kawecka-Jaszcz K, Czarnecka D, Brzozowska-Kiszka M, Styczkiewicz K, Loster M, Kloch-Bade?ek M, Wili?ski J, Cury?o AM, Dudek D; Aortic Blood Pressure and Survival Study Group. Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients. Hypertension 2008; 51:848-855.
23. Karamanoglu M, O'Rourke MF, Avolio AP, Kelly RP. An analysis of the relationship between central aortic and peripheral upper limb pressure waves in man. Eur Heart J 1993; 14:160-167.
24. Benetos A, Tsoucaris-Kupfer D, Favereau X, Corcos T, Safar M. Carotid artery tonometry: An accurate non-invasive method for central aortic pulse pressure evaluation. J Hypertens Suppl 1991; 9:S144-S145.
25. Williams B, Lacy PS, Yan P, Hwee CN, Liang C, Ting CM. Development and validation of a novel method to derive central aortic systolic pressure from the radial pressure waveform using an n-point moving average method. J Am Coll Cardiol 2011; 57:951-961.
26. Cheng HM, Wang KL, Chen YH, Lin SJ, Chen LC, Sung SH, Ding PY, Yu WC, Chen JW, Chen CH. Estimation of central systolic blood pressure using an oscillometric blood pressure monitor. Hypertens Res 2010; 33:592-599.
27. Weber T, Wassertheurer S, Rammer M, Maurer E, Hametner B, Mayer CC, Kropf J, Eber B. Validation of a brachial cuff-based method for estimating central systolic blood pressure. Hypertension 2011; 58:825-832.
28. Shih YT, Cheng HM, Sung SH, Hu WC, Chen CH. Application of the N-point moving average method for brachial pressure waveformderived estimation of central aortic systolic pressure. Hypertension 2014; 63:865-870.
29. Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, Gibbons RJ, Halperin JL, Hlatky MA, Jacobs AK, Mark DB, Masoudi FA, Peterson ED, Shaw LJ. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: A report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:2304-2322.
30. Karnon J, Vanni T. Calibrating models in economic evaluation: A comparison of alternative measures of goodness of fit, parameter search strategies and convergence criteria. Pharmacoeconomics 2011; 29:51-62.
31. Vanni T, Karnon J, Madan J, White RG, Edmunds WJ, Foss AM, Legood R. Calibrating models in economic evaluation: A seven-step approach. Pharmacoeconomics 2011; 29:35-49.
32. Cheng HM, Sung SH, Chuang SY, Pearson A, Tufanaru C, White S, Yu WC, Chen CH. Diagnostic performance of a stand-alone central blood pressure monitor: Application of central blood pressure in the diagnosis of high blood pressure. Am J Hypertens 2014; 27:382-391.
33. Lovibond K, Jowett S, Barton P, Caulfield M, Heneghan C, Hobbs FD, Hodgkinson J, Mant J, Martin U, Williams B, Wonderling D, McManus RJ. National Clinical Guideline Centre. Appendix J: cost-effectiveness analysis-blood pressure monitoring for confirming a diagnosis of hypertension. In Hypertension: Clinical Management of Primary Hypertension in Adults. National Clinical Guideline Centre: London, 2011, pp. P446-P502.
34. Lovibond K, Jowett S, Barton P, Caulfield M, Heneghan C, Hobbs FD, Hodgkinson J, Mant J, Martin U, Williams B, Wonderling D, McManus RJ. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: A modelling study. Lancet 2011; 378:1219-1230.
35. Office for National Statistics (ONS). Mortality Statistics: Deaths Registered in 2010, 2011.
36. Genders TS, Meijboom WB, Meijs MF, Schuijf JD, Mollet NR, Weustink AC, Pugliese F, Bax JJ, Cramer MJ, Krestin GP, de Feyter PJ, Hunink MG. CT coronary angiography in patients suspected of having coronary artery disease: decision making from various perspectives in the face of uncertainty. Radiology 2009; 253:734-744.
37. National Centre for Social Research and University College London. Department of Epidemiology and Public Health. Health Survey for England 2006, 3rd edn, Vol 2. UK Data Archive: Colchester, 2010.
38. Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007; 11:1-160, iii-iv.
39. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.
40. Koehler E, Brown E, Haneuse SJ. On the Assessment of Monte Carlo Error in Simulation-Based Statistical Analyses. Am Stat 2009; 63:155-162.
41. Spearman C. The proof and measurement of association between two things. By C. Spearman, 1904. Am J Psychol 1987; 100:441-471.
42. Hughes MD. Regression dilution in the proportional hazards model. Biometrics 1993; 49:1056-1066.
43. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: A meta-analysis. J Hypertens 2007; 25:2193-2198.
44. Huang CM, Wang KL, Cheng HM, Chuang SY, Sung SH, Yu WC, Ting CT, Lakatta EG, Yin FC, Chou P, Chen CH. Central versus ambulatory blood pressure in the prediction of all-cause and cardiovascular mortalities. J Hypertens 2011; 29:454-459.
45. Hodgkinson J, Mant J, Martin U, Guo B, Hobbs FD, Deeks JJ, Heneghan C, Roberts N, McManus RJ. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review. BMJ 2011; 342:d3621.
46. Fagard RH, Staessen JA, Thijs L. Prediction of cardiac structure and function by repeated clinic and ambulatory blood pressure. Hypertension 1997; 29:22-29.
47. Imai Y, Ohkubo T, Sakuma M, Tsuji I I, Satoh H, Nagai K, Hisamichi S, Abe K. Predictive power of screening blood pressure, ambulatory blood pressure and blood pressure measured at home for overall and cardiovascular mortality: A prospective observation in a cohort from Ohasama, northern Japan. Blood Press Monit 1996; 1:251-254.
48. Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, Pessina A, Porcellati C, Rappelli A, Salvetti A, Trimarco B, Agebiti-Rosei E, Pessino A. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 1997; 95:1464-1470.
49. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999; 282:539-546.
50. Verdecchia P. Prognostic value of ambulatory blood pressure: current evidence and clinical implications. Hypertension 2000; 35:844-851.
51. Wald DS, Simmonds MC, Morris JK, Rothwell PM, Wald NJ. Costeffectiveness of diagnosis of high blood pressure in primary care. Lancet 2012; 379:709-10; author reply 710.
52. Sharman JE, Laurent S. Central blood pressure in the management of hypertension: soon reaching the goal? J Hum Hypertens 2013; 27:405-411.
53. McEniery CM, Yasmin, Hall IR, Qasem A, Wilkinson IB, Cockcroft JR. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol 2005; 46:1753-1760.
54. McEniery CM, Yasmin, McDonnell B, Munnery M, Wallace SM, Rowe CV, Cockcroft JR, Wilkinson IB. Central pressure: variability and impact of cardiovascular risk factors: the Anglo-Cardiff Collaborative Trial II. Hypertension 2008; 51:1476-1482.
55. Sharman JE, Marwick TH, Gilroy D, Otahal P, Abhayaratna WP, Stowasser M; Value of Central Blood Pressure for GUIDing ManagEment of Hypertension Study Investigators. Randomized trial of guiding hypertension management using central aortic blood pressure compared with best-practice care: principal findings of the BP GUIDE study. Hypertension 2013; 62:1138-1145.
56. Staessen JA, Byttebier G, Buntinx F, Celis H, O'Brien ET, Fagard R. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators. JAMA 1997; 278:1065-1072.
57. Asayama K, Ohkubo T, Metoki H, Obara T, Inoue R, Kikuya M, Thijs L, Staessen JA, Imai Y; Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure (HOMED-BP). Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertens Res 2012; 35:1102-1110.
58. Den Hond E, Staessen JA, Celis H, Fagard R, Keary L, Vandenhoven G, O'Brien ET; Treatment of Hypertension Based on Home or Office Blood Pressure (THOP) Trial Investigators. Antihypertensive treatment based on home or office blood pressure-the THOP trial. Blood Press Monit 2004; 9:311-314.
59. Staessen JA, Den Hond E, Celis H, Fagard R, Keary L, Vandenhoven G, O'Brien ET; Treatment of Hypertension Based on Home or Office Blood Pressure (THOP) Trial Investigators. Antihypertensive treatment based on blood pressure measurement at home or in the physician's office: A randomized controlled trial. JAMA 2004; 291:955-964.
60. Craig R, Mindell J. Health Survey for England 2006. Volume 1: Cardiovascular Disease and Risk Factors in Adults. The NHS Information Centre for Health and Social Care: London, 2008.
61. Miller JM, Rochitte CE, Dewey M, et al. Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med. 2008;359:2324-2336.
62. Bronnum-Hansen H, Jorgensen T, Davidsen M, et al. Survival and cause of death after myocardial infarction: the Danish MONICA study. J Clin Epidemiol. 2001;54:1244-1250.
63. Crowe E, Lovibond K, Gray H, Henderson R, Krause T, Camm J; Guideline Development Group. Early management of unstable angina and non-ST segment elevation myocardial infarction: summary of NICE guidance. BMJ. 2010;340:c1134.
64. Rosengren A, Wilhelmsen L, Hagman M, Wedel H. Natural history of myocardial infarction and angina pectoris in a general population sample of middle-aged men: A 16-year follow-up of the Primary Prevention Study, Göteborg, Sweden. J Intern Med. 1998;244:495-505.
65. Bronnum-Hansen H, Davidsen M, Thorvaldsen P; Danish MONICA Study Group. Long-term survival and causes of death after stroke. Stroke. 2001;32:2131-2136.
66. Dennis M, Bamford J, Sandercock P, Warlow C. Prognosis of transient ischemic attacks in the Oxfordshire Community Stroke Project. Stroke. 1990;21:848-853.
67. Product Information of Central Blood Pressure Monitors, 2012.
68. Personal Social Services Research Unit. Unit Costs of Health and Social Care, 2010.
69. Palmer S, Sculpher M, Philips Z, et al. Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service? Int J Cardiol. 2005;100:229-240.
70. Joint Formulary Committee. British National Formulary 60. BMJ Group and Pharmaceutical Press: London, 2010.
71. Department of Health. NHS Reference Costs 2009-2010. Department of Health: London, 2011.
72. National Clinical Guideline Centre for Acute and Chronic Conditions. Stable Angina: Draft Full Guideline for Consultation. National Clinical Guideline Centre: London, 2010.
73. Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the United Kingdom. Pharmacoeconomics. 2003;21 Suppl 1:43-50.
74. Cooper A, O'Flynn N; Guideline Development Group. Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance. BMJ. 2008;336:1246-1248.
75. Greenhalgh J, Bagust A, Boland A, et al. Clopidogrel and modifiedrelease dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): A systematic review and economic analysis. Health Technol Assess. 2011;15:1-178.